Gan & Lee Pharmaceuticals. (603087.SS)
CNY 45.54
(0.35%)
CNY 45.54
(0.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 315.28 Million CNY | 131.91% |
| 2022 | -564.27 Million CNY | -133.21% |
| 2021 | 1.69 Billion CNY | 16.93% |
| 2020 | 1.45 Billion CNY | 3.93% |
| 2019 | 1.39 Billion CNY | 25.48% |
| 2018 | 1.11 Billion CNY | -12.26% |
| 2017 | 1.26 Billion CNY | 41.08% |
| 2016 | 900 Million CNY | 72.37% |
| 2015 | 522.12 Million CNY | 50.36% |
| 2014 | 347.25 Million CNY | 48.48% |
| 2013 | 233.87 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 93.81 Million CNY | 5832.44% |
| 2024 Q1 | -1.63 Million CNY | 93.62% |
| 2024 Q3 | 222.9 Million CNY | 137.6% |
| 2023 Q3 | 153.17 Million CNY | 46.97% |
| 2023 Q1 | 59.82 Million CNY | 142.56% |
| 2023 Q2 | 104.21 Million CNY | 74.2% |
| 2023 Q4 | -25.64 Million CNY | -116.74% |
| 2023 FY | 180.03 Million CNY | 131.91% |
| 2022 Q1 | 213.26 Million CNY | -68.38% |
| 2022 FY | -564.27 Million CNY | -133.21% |
| 2022 Q2 | -417.69 Million CNY | -295.86% |
| 2022 Q4 | -140.57 Million CNY | 18.75% |
| 2022 Q3 | -173.02 Million CNY | 58.58% |
| 2021 FY | 1.69 Billion CNY | 16.93% |
| 2021 Q4 | 674.38 Million CNY | 22.28% |
| 2021 Q3 | 551.51 Million CNY | 134.76% |
| 2021 Q2 | 234.92 Million CNY | -1.33% |
| 2021 Q1 | 238.08 Million CNY | -61.04% |
| 2020 Q1 | 153.59 Million CNY | -73.47% |
| 2020 FY | 1.45 Billion CNY | 3.93% |
| 2020 Q4 | 611.18 Million CNY | 32.61% |
| 2020 Q3 | 460.88 Million CNY | 102.81% |
| 2020 Q2 | 227.24 Million CNY | 47.95% |
| 2019 Q1 | 120.75 Million CNY | 0.0% |
| 2019 FY | 1.39 Billion CNY | 25.48% |
| 2019 Q4 | 579.04 Million CNY | 22.02% |
| 2019 Q3 | 474.56 Million CNY | 112.3% |
| 2019 Q2 | 223.54 Million CNY | 85.12% |
| 2018 FY | 1.11 Billion CNY | -12.26% |
| 2017 Q2 | 215.54 Million CNY | 0.0% |
| 2017 FY | 1.26 Billion CNY | 41.08% |
| 2017 Q1 | 215.54 Million CNY | 0.0% |
| 2016 FY | 900 Million CNY | 72.37% |
| 2015 FY | 522.12 Million CNY | 50.36% |
| 2014 FY | 347.25 Million CNY | 48.48% |
| 2013 FY | 233.87 Million CNY | 0.0% |